Key Takeaways
- FY25 delivered 15% revenue growth, Q4 accelerated to 20% YoY: Volume-led expansion across all business areas, with Domestic Branded Generics and International Business growing fastest at 30% and 47% in Q4 respectively.
- Kathua plant is the FY26 story: Commercial production began January 2025, and management is "very much confident" of achieving ₹400 crores incremental revenue from the Jammu facility in FY26, broken across four blocks.
- Sharon's flat revenue has a clear revival thesis: Revenue stagnated for ~4 years because the asset was in CIRP with no new initiatives; post-integration projects are now maturing, and management expects positivity to reflect in the upcoming year.
- Margins improved but exact targets are withheld: Gross margin expansion came from operational efficiency and better product mix; management says margins are "bound to increase" with operating leverage but declined to commit to a specific number.
- What to watch next quarter: Whether Jammu revenue ramps on the ₹25 crores-per-block-per-quarter trajectory, whether Sharon's regulated-market projects begin converting, and whether working capital normalizes as promised.
The Jammu Catalyst: Kathua Plant Ramp-Up
- Four-block structure de-risks the ramp: The ₹400 crores FY26 target divides into ~₹100 crores per block, or ~₹25 crores per block per quarter, which management argues makes the number "smaller" and more achievable than it appears in aggregate.
- Break-even is low relative to the target: The plant reaches EBITDA neutrality at around ₹50-55 crores of sales, meaning the first two blocks' quarterly run-rate already covers fixed costs.
- Cannibalization is real but contained: Some revenue has already moved from the existing Cepha facility in Baddi to the new Jammu Cepha block, so Baddi standalone numbers understate the true performance of the legacy business.
- Depreciation burden is known: Jammu plant carries ₹24-25 crores of annual depreciation, which Q4 PAT already began absorbing; existing business depreciation continues at similar levels with possible maintenance capex.
- Operations proved resilient: The facility operated without a single day of shutdown through regional tensions, confirming supply-chain continuity for CDMO clients.
Lohariwala: "So as on date, we are very much confident that this number is achievable. And being four facility, so say, if we say, like INR400 crores, sometimes it looks quite aggressive. But if we divide in the four plants, so it's not 1 facility, but there are four block. So, it's like INR100 crores. And each quarter, if we see, then it come out to be, let's say, INR25 crores each block. So, then the number becomes smaller."
Sharon: The Regulated-Market Turnaround Bet
- Four years of flat revenue, one structural reason: Sharon was in CIRP (corporate insolvency resolution process) with no new initiatives taken; the business was essentially frozen until Innova Captab integrated it roughly 1.5 years ago.
- The gestation gap is now closing: New projects were started post-integration, and because regulated markets carry long lead times for product approvals and customer onboarding, those projects are only now maturing into revenue.
- Strategy rests on three legs: Onboarding new customers, expanding wallet share with existing customers via new products, and reviving business relationships that were active 4-5 years ago before the CIRP disruption.
- Margin profile is structurally better: Sharon carries a slightly superior gross margin profile versus Innova Captab's manufacturing capabilities because it operates predominantly in regulated export markets.
- R&D investment supports the thesis: The upcoming Panchkula R&D facility will develop complex generics (super bioavailability capsules, nano-size formulations) that directly feed Sharon's regulated-market pipeline across Europe, Canada, and Australia.
Lohariwala: "So, as you are aware that Sharon being in CIRP, there were no new initiation, new steps has been taken. Once we integrate -- and I think June -- to 1.5 year back, then we start taking new projects and all that. So that will mature in the coming quarters and coming year as there is a long lead time for -- long gestation time for in a regulated market."
Domestic Branded Generics: The Volume Engine
- Distribution is the moat, and it is widening: The network expanded from 5,000 to 6,000 distributors and from 150,000 to 220,000-plus pharmacies and stockists in FY25, driving 21% full-year growth and 30% in Q4.
- Product portfolio deepened alongside reach: The domestic offering grew from 600-plus to over 750 products, giving the expanded distribution force more to sell into each territory.
- Growth is volume-led, not price-led: Management confirmed the 21% growth was driven by volumes through new products, new market penetration, and deepening existing market presence.
- Future growth should track the company average: Management expects Domestic Branded Generics growth to remain "in line with overall company growth," implying no expectation of the segment pulling ahead or falling behind the blended rate.
CDMO & International: Steady Base, New Geography
- CDMO grew 6% for the full year, 12% in Q4: The acceleration was driven by sustained traction in existing products plus initial contribution from the new Kathua facility, which began offering new products and dosage forms in January.
- Client base crossed 200 customers: The CDMO business now serves some of the largest Indian pharmaceutical players, and the strategy is to acquire new clients while increasing wallet share from existing partners.
- International business surged 47% in Q4: Presence expanded from 25-plus to 30-plus countries, including new entries into the UK and Canada; growth came from both product and market expansion.
- API pricing is broadly stable: At a weighted average level, prices are more or less flat; cephalosporin and beta-lactam prices are slightly lower, but some areas saw increases that offset the declines.
- Product mix, not price, drove CDMO growth: Any price impact was "knocked off by product mix and other variable reasons," with only a 1-2% variation attributable to pricing.
Margins & Working Capital: Direction Clear, Precision Absent
- Gross margin improved on three levers: Operational efficiency, better product mix, and optimal use of resources drove the expansion, and management expects the same trajectory to continue.
- Operating leverage is the margin thesis: Management argues that as operations increase, economies of scale, GST benefits, and new product contributions will push margins higher, but declined to put a number on the target when asked if 17% was achievable in three years.
- Segment-level margins are a black box: Management stated twice that it does not track gross margins or margin profiles at the business-area level, so investors cannot see whether Sharon, CDMO, or Domestic Branded Generics is the margin leader.
- Working capital swelled for a transitional reason: The increase was driven by higher operations plus the initial working capital required to start the Jammu plant; management is "hopeful" it normalizes in coming times.
- R&D spend will be immaterial at scale: At the current ~₹1,200 crores revenue base, ₹50-100 crores of R&D-driven business has limited margin impact; at the targeted ₹2,500 crores scale, the impact would be negligible.
The 25% CAGR Ambition
- Three-year revenue CAGR target of 25%: Management expressed confidence in maintaining this growth rate over the next three years, implying a revenue base of roughly ₹2,400-2,500 crores by FY28.
- The math requires both Jammu and the base business to fire: Jammu contributes ₹400 crores in FY26; existing (non-Jammu) facilities are expected to grow at "early teens," and Sharon's revival must add incremental regulated-market revenue.
- No margin commitment accompanies the revenue target: While management says margins are "bound to increase" with scale, it declined to quantify the trajectory, leaving investors to model their own assumptions.
- Depreciation and finance costs are the known drags: Jammu's ₹24-25 crores annual depreciation and associated finance costs are already flowing through the P&L, and Q4 PAT growth of just 3% (versus 20% revenue growth) shows the absorption phase is underway.
Lohariwala: "By increase of operations, operating leverage, GST benefit, economies of scale, and new products, margin is bound to increase."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu (Kathua) plant revenue | ₹400 crores incremental revenue | FY26 |
| Jammu block-level ramp | ~₹25 crores per block per quarter across four blocks | FY26 |
| Jammu break-even | EBITDA neutral at ₹50-55 crores of sales | FY26 (implied early in ramp) |
| Existing facilities growth | Early teens percentage growth | FY26 |
| Long-term revenue CAGR | 25% CAGR | Next 3 years (FY26-FY28) |
| Sharon turnaround | Positivity to reflect as new projects mature | Upcoming year (FY26) |
| Working capital | Normalize to normal days | "Coming times" (no date) |
| Gross margin trajectory | Maintain same trajectory | Going forward |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated revenue | ₹314.7 cr, ~20% YoY growth |
| CDMO revenue | ₹154.8 cr, +12% YoY |
| Domestic Branded Generic revenue | ₹61.7 cr, +30% YoY |
| International Branded Generic revenue | ₹43.4 cr, +47% YoY |
| Sharon revenue | ₹54.9 cr, +15% YoY |
| EBITDA | ₹51.1 cr, +17% YoY |
| EBITDA margin | 16.2% |
| PAT | ₹29.6 cr, +3% YoY |
| PAT margin | 9.4% |
| Jammu plant revenue contribution | ₹36 cr, commercialized from Jan 14, 2025 |
| Jammu plant FY26 revenue guidance | ₹400 cr, including GST benefit of ₹30–35 cr |
| Jammu plant EBITDA breakeven | ₹50–55 cr of sales |
| Jammu plant annual depreciation | ₹24–25 cr |
| CDMO client base | Over 200 customers, up from prior year |
| Product portfolio | Over 3,300 products, up from 2,900-plus |
| Domestic distribution network | Over 6,000 distributors, up from 5,000 |
| Market reach | Over 220,000 pharmacies and stockists, up from 150,000 |
| International presence | 30-plus countries, up from 25-plus |